Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus

Overview

Journal Acta Naturae

Specialty Biology

Date 2024 May 3

PMID 38698957

Authors

D V Shcheblyakov

D V Voronina

I A Favorskaya

I B Esmagambetov

I A Alekseeva

A I Korobkova

E I Ryabova

A A Derkaev

V Yu Kan

A Sh Dzharullaeva

A I Tukhvatulin

A S Bandelyuk

M M Shmarov

D Yu Logunov

A L Gintsburg

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies and recombinant antibody fragments are a very promising therapeutic tool to combat infectious diseases. Due to their unique paratope structure, nanobodies (VHHs) hold several advantages over conventional monoclonal antibodies, especially in relation to viral infections. Influenza A viruses (IAVs) remain a major threat to public health. The hemagglutinin (HA) protein is the main protective and immunodominant antigen of IAVs. In this study, three broadly reactive nanobodies (D9.2, E12.2, and D4.2) to H3N2 influenza strains were isolated and Fc-fusion proteins (VHH-Fcs) were obtained and characterized . This modification improved the nanobodies' binding activity and allowed for their interaction with a wider range of strains. The D9.2-Fc antibody showed a 100% protection rate against mortality in a mouse lethal model. Furthermore, we demonstrated that the observed protection has to do with Fc-FcγR interactions. These results indicate that D9.2-Fc can serve as an effective antiviral agent against the H3N2 influenza infection.

Citing Articles

Single domain antibody: Development and application in biotechnology and biopharma.

Yu T, Zheng F, He W, Muyldermans S, Wen Y Immunol Rev. 2024; 328(1):98-112.

PMID: 39166870 PMC: 11659936. DOI: 10.1111/imr.13381.

References

Huang K, Ying T, Wu Y . Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections. Viruses. 2022; 14(6). PMC: 9230756. DOI: 10.3390/v14061162. View

Tutykhina I, Sedova E, Gribova I, Ivanova T, Vasilev L, Rutovskaya M . Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Res. 2013; 97(3):318-28. DOI: 10.1016/j.antiviral.2012.12.021. View

Benhaim M, Mangala Prasad V, Garcia N, Guttman M, Lee K . Structural monitoring of a transient intermediate in the hemagglutinin fusion machinery on influenza virions. Sci Adv. 2020; 6(18):eaaz8822. PMC: 7190341. DOI: 10.1126/sciadv.aaz8822. View

Burmistrova D, Tillib S, Shcheblyakov D, Dolzhikova I, Shcherbinin D, Zubkova O . Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis. PLoS One. 2016; 11(3):e0150958. PMC: 4786110. DOI: 10.1371/journal.pone.0150958. View

He W, Mullarkey C, Miller M . Measuring the neutralization potency of influenza A virus hemagglutinin stalk/stem-binding antibodies in polyclonal preparations by microneutralization assay. Methods. 2015; 90:95-100. DOI: 10.1016/j.ymeth.2015.04.037. View

Kumar S, Athreya A, Gulati A, Nair R, Mahendran I, Ranjan R . Structural basis of inhibition of a transporter from Staphylococcus aureus, NorC, through a single-domain camelid antibody. Commun Biol. 2021; 4(1):836. PMC: 8257674. DOI: 10.1038/s42003-021-02357-x. View

Kaverin N, Rudneva I, Govorkova E, Timofeeva T, Shilov A, Kochergin-Nikitsky K . Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol. 2007; 81(23):12911-7. PMC: 2169086. DOI: 10.1128/JVI.01522-07. View

Hultberg A, Temperton N, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B . Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS One. 2011; 6(4):e17665. PMC: 3069976. DOI: 10.1371/journal.pone.0017665. View

Yoon A, Yi K, Chang S, Kim S, Song M, Choi J . An Anti-Influenza Virus Antibody Inhibits Viral Infection by Reducing Nucleus Entry of Influenza Nucleoprotein. PLoS One. 2015; 10(10):e0141312. PMC: 4626144. DOI: 10.1371/journal.pone.0141312. View

10.

Voronina D, Shcheblyakov D, Esmagambetov I, Derkaev A, Popova O, Shcherbinin D . Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses. Acta Naturae. 2022; 13(4):33-41. PMC: 8807538. DOI: 10.32607/actanaturae.11495. View

11.

Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, Pareek M . Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009; 48(4):389-96. DOI: 10.1086/596311. View

12.

McCarthy K, Watanabe A, Kuraoka M, Do K, McGee C, Sempowski G . Memory B Cells that Cross-React with Group 1 and Group 2 Influenza A Viruses Are Abundant in Adult Human Repertoires. Immunity. 2018; 48(1):174-184.e9. PMC: 5810956. DOI: 10.1016/j.immuni.2017.12.009. View

13.

Mausser E, Nador E, Politch J, Pauly M, Marathe J, Moench T . LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity. PLoS One. 2023; 18(3):e0282147. PMC: 10062632. DOI: 10.1371/journal.pone.0282147. View

14.

Lewnard J, Cobey S . Immune History and Influenza Vaccine Effectiveness. Vaccines (Basel). 2018; 6(2). PMC: 6027411. DOI: 10.3390/vaccines6020028. View

15.

Hanke L, Das H, Sheward D, Perez Vidakovics L, Urgard E, Moliner-Morro A . A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Nat Commun. 2022; 13(1):155. PMC: 8748511. DOI: 10.1038/s41467-021-27610-z. View

16.

Burrell A, Huckson S, Pilcher D . ICU Admissions for Sepsis or Pneumonia in Australia and New Zealand in 2017. N Engl J Med. 2018; 378(22):2138-2139. DOI: 10.1056/NEJMc1717178. View

17.

Son S, Ahn S, Kim G, Jang Y, Ko C, Kim M . Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice. Antiviral Res. 2023; 213:105591. DOI: 10.1016/j.antiviral.2023.105591. View

18.

Iba Y, Fujii Y, Ohshima N, Sumida T, Kubota-Koketsu R, Ikeda M . Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses. J Virol. 2014; 88(13):7130-44. PMC: 4054433. DOI: 10.1128/JVI.00420-14. View

19.

Benjamin E, Wang W, McAuliffe J, Palmer-Hill F, Kallewaard N, Chen Z . A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. J Virol. 2014; 88(12):6743-50. PMC: 4054378. DOI: 10.1128/JVI.03562-13. View

20.

Liu H, Wu L, Liu B, Xu K, Lei W, Deng J . Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice. Cell Rep Med. 2023; 4(2):100918. PMC: 9834170. DOI: 10.1016/j.xcrm.2023.100918. View